Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron PharmafiledCriticalRegeneron Pharma
Publication of AR115423A2publicationCriticalpatent/AR115423A2/en
La presente proporciona anticuerpos que se unen a la angiopoyetina-2 (Ang-2) y métodos para el uso de los mismos. Según ciertas realizaciones de la presente, los anticuerpos son anticuerpos humanos completos que se unen a la Ang-2 humana. Los anticuerpos de la presente son útiles, entre otras cosas, para el tratamiento de enfermedades y trastornos asociados con una o más actividades biológicas de la Ang-2 incluyendo la angiogénesis.The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods for the use thereof. According to certain embodiments herein, the antibodies are whole human antibodies that bind to human Ang-2. The antibodies herein are useful, among other things, for the treatment of diseases and disorders associated with one or more biological activities of Ang-2 including angiogenesis.
ARP190101402A2009-07-292019-05-24
HUMAN ANTIBODIES OF HIGH AFFINITY FOR HUMAN ANGIOPOYETIN-2
AR115423A2
(en)